Member Info for Marcus134

Berm

https://x.com/neobio_mabs/status/1957865407160742203

Moderna results are in resected patients. Scancell results are in advanced unresectable stage III/IV melanoma ( melanoma that has spread to distant parts of the body or is not surgically removable (unresectable).)

If Scancell can produce the goods with an off the shelf Modi-1 vaccine then they may book that stretch limousine again and head back to Roche for a second try!

The global market for head and neck cancer anticipated to reach $8.1 billion by 2031

Ovarian Cancer USD 4.68 billion in 2023

RCC drugs in 2023 are estimated to total US$8.1 billion

If successful and Modi-1 even gets a small percentage of that market. Off the shelf vaccine.

iScib-1

Opportunity in Unresectable Melanoma $3bn

Opportunity in Neoadjuvant/Adjuvant Melanoma $6-9bn

Growth opportunity as a Preventative Vaccine Patients (Early identifiable at-risk groups)

Glymab Therapeutics $ who knows?

Who puts up the money plus Sc129 and Sc134 data may give us a better idea.

Has Avidimab contributed to that fantastic PFS 0f 80% from month 4 to 11 with iScib-1 ?

So we have seen 44% with Modi-1 on its own as a monotherapy. Big Pharma loves to see that it works independently.

If the RCC with CPIs produces then I would imagine interest will really ramp up.

Platform technology, Modi-1 Modi-2 Modi-3

HPV negative head and neck squamous cell carcinoma (SCCHN)25-week scan. This equates to an ORR of 43% compared to historical ORRs of 19% for Pembrolizumab and 13% for nivolumab

Ovarian

16 patients scanned and 7 stable

responses by RECIST (44%). Stable disease

= between 20% and -30% change in target

lesion size with no new lesions present

Should see stronger responses in

combination with CPIs particularly antiPD1 and anti-CTLA4 but these are not

approved for ovarian cancer

consider a new cohort with HCC where

the double CPIs are indicated and then

persuade pharma to combine Modi-1

with double CPIs in ovarian cancer

Kidney RCC next. Will Modi-1 with Ipi/Nivo produce good results?

Https://www.onclive.com/view/rp1-an-emerging-intratumoral-therapy

https://www.oncologynewscentral.com/melanoma/fda-rejects-oncolytic-virus-combination-for-advanced-melanoma

Https://www.biotechtv.com/post/io-biotech-august-15-2025

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

Kidney is obviously a much more difficult cancer but I have everything crossed that we can improve on the SOC for RCC Ipi/Nivo.

Modi1 in combination with CPIs in advanced renal cell carcinoma (RCC) 44 previously untreated patients

This is the main stat.

Scib-1 maintained 64.6% PFS from 11 months to 22 months without dropping.

iScib-1 PFS maintained 80.8% from 4 to 11 months.

Ipi/Nivo PFS 50% at 11 months dropping to 42% at 22 months.

Https://www.onclive.com/view/investigational-neoantigen-vaccines-target-rcc-mutations-and-drive-durable-t-cell-activity

Yes that is talking about the same vaccine Violindog.

The study, published in the journal Nature Medicine, tested the jab on 20 patients with pancreatic cancer and five with bowel cancer.

When participants were followed up after 20 months, 68 per cent had developed strong immune responses specific to mutant KRAS tumour proteins.

Participants who had the strongest immune responses lived and stayed cancer-free for longer than those with weaker responses.

(any vaccine success helps Scancell)

#KRAS Vaccine💉for patients with RAS➕cancers🎯.

Benefit➡️durable.🙌🏽

More to come with the randomized study📚✔️!

Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations.

Often I get asked the question: Which specific mutations is the 7️⃣-PEPTIDE vaccine💉active against❓ Here’s a nice infographicℹ️

@DrawImpacts

. G12➖ D R V S A C & G13D And also interestingly serendipitously it’s not just a🎯KRAS-vaccine but also🎯an NRAS-vaccine.

@OncoAlert

https://www.nature.com/articles/s41591-025-03876-4

https://x.com/pashtoonkasi/status/1954962381286805835

Https://www.fiercebiotech.com/biotech/cancer-vaccines-narrow-phase-3-fail-wont-stop-io-heading-fda

Inanaco 11 Aug '25 - 18:55 -

this was the one trial i though might give us a run for our money ..........

now the GOOD NEWS

hTTps://scancell.co.uk/wp-content/uploads/2024/11/agm-october-2024.pdf

slide 7

Scancell identified Io Biotech and Biontech as competition

seems .... they are NOT

Stakis,

as far as I can see they failed to hit their goal. Scancell has produced the best data that I have seen in advanced Melanoma so good for us.

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with Merck’s (MRK) Keytruda, failed to achieve statistical significance in progression-free survival improvement in a late-stage trial compared to Keytruda alone.

Opportunity in

Unresectable Melanoma

iSCIB1+

**HLA-A allele frequencies by country in Europe, the Near East & North Africa – Eupedia

*Management Estimates, global patient population estimated for 2038

Current

Patient population

38,000

Target HLA** Market

Potential market size*

$3bn

Opportunity in

Neoadjuvant/Adjuvant Melanoma

iSCIB1+

Patient population

129,000

Target HLA** Market

Potential market size*

$6-9bn

Https://iobiotech.com/press-releases/?workflow=6562e614-30a0-4300-9a37-ab75253933a2

If Glymab therapeutics gets funding to take SC134 bispecific through phase I. Good data could result in a very valuable asset.

100% survival against CT26 colorectal cancer

70% survival against 4T1 breast cancer

We demonstrate that human lung, colorectal, breast and prostate tumours express the antigens that are targets of the Modi-2 vaccine.

100% survival against CT26 colorectal cancer (p

modi-2 may be even better with the snapvax tech.

here we demonstrate the use of a self-assembling nanoparticle technology (snapvax tm ) to co-deliver four ****citrullinated peptides and adjuvant in nanoparticles of a precise size and composition as a vaccine (“modi-2”) that is optimized for manufacturing ease and t cell induction. the vaccine stimulated strong th1 cell responses and anti-tumour immunity in mouse tumour models with 40% overall survival against b16 melanoma (p=0.0113), 100% survival against ct26 colorectal cancer (p